Sensei Biotherapeutics discontinues solnerstotug, initiates strategic review for sale or wind-down

Sensei Biotherapeutics, Inc.

Board discontinues development of solnerstotug after review of pipeline and market conditions.
Initiated comprehensive review of strategic alternatives, including sale, merger, licensing, or orderly wind-down.
Workforce reduction planned to preserve cash; details to be disclosed separately.
Small team retained to assist with strategic review, regulatory compliance, and orderly cessation of development.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.